Australia's most trusted
source of pharma news
Posted 18 May 2022 AM
A cheap and widely used oral corticosteroid drug, methylprednisolone, halves the risk of losing kidney function and kidney failure in patients with IgA nephropathy, a global study has found.
Four companies' market either injectable or topical methylprednisolone in Australia including Leo Pharma, MedTAS, Pfizer and Sun Pharma. There are no oral formulations registered locally.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.